Rational Vaccines Licenses Promising Technology from Louisiana State University
Vaccine candidate VC2 shows promise for herpes treatment
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ Rational Vaccines today announced a license agreement for the work of leading Louisiana State University virologist Dr. Konstantin Gus Kousoulas from LSU s School of Veterinary Medicine in the Division of Biotechnology & Molecular Medicine (BioMMED) that furthers Rational s core mission of eliminating the herpes virus. The vaccine technology, known as VC2, demonstrated great promise in the treatment of Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) as well as facial and ocular herpes in a number of animal model studies.
Study validates pre-clinical safety of novel live-attenuated HSV-2 vaccine candidates prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ Leading virologist Konstantin Gus Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company s core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
(PRNewsfoto/Rational Vaccines) Dr. Kousoulas is one of the world s most eminent virologists. His work in the field of HSV gives hopes to the millions of patients who are in desperate need of a better standard of care and to all of us who work to defeat this heinous virus, said Rational Vaccines CEO Agustin Fernandez. No one understands this virus better than Gus. His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic.
The NIH Treatment Guidelines Panel recently changed ivermectin from firmly “against” to the neutral “neither for nor against” when it comes to mild COVID-19 treatment. Ivermectin, developed in 1975, led to the eradication of numerous parasitic diseases and earned the 2015 Nobel Prize for Physiology or Medicine for its discoverers, Dr.
The major finding of the study, Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice, found that the company s RVX101 vaccine candidate used to immunize a unique mouse line (does not generate much of a neutralizing antibody response to the virus) was shown to provide highly protective immunity and prevent herpes-associated neovascularization. This robust efficacy was found to be correlated with CD8+ T cells, since depleting these cells after vaccination, but before challenge with HSV-1 eliminated any efficacy realized by the vaccine.
Ocular HSV can cause disease in any layer of the eye and is mainly spread by direct contact. A variety of eye diseases are associated with ocular HSV infection, including conjunctivitis, iridocyclitis, acute retinal necrosis and keratitis.